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NMLEAbstract Purpose: The purpose of our study was to evaluate the diagnostic value of an imaging
protocol that combines dynamic contrast-enhanced MRI (DCE-MRI) and apparent diffusion coef-
ﬁcient (ADC), measured by diffusion weighted MRI, in discriminating benign and malignant breast
lesions presenting as mass and non mass like enhancement (NMLE).
Methods and materials: 80 patients with 110 breast lesions identiﬁed with dynamic contrast MRI.
Diffusion-weighted images were obtained at b values of 0 and 750 S/mm2, differences in the appar-
ent diffusion coefﬁcients (ADCs) are included in the study and malignant lesions were compared by
lesion type (mass or NMLE), and the analysis was performed to evaluate diagnostic performance
based on ADC thresholds. All lesions have pathological results. The study has been done retrospec-
tively 50 patients underwent surgical excision with preoperative localization, while the 30 cases
underwent stereotactic biopsies either US or mammographically guided techniques specially if asso-
ciated with micro calciﬁcations.
Results: The mean ADC value of all benign lesions is 1.41 ± 0.36 · 103 mm2/s, which is higher
than the mean ADC of all malignant lesions (1.05 ± 0.30 · 103 mm2/s, p< 0.05). In the MASS
type, the mean ADC is higher in the benign group (1.34 ± 0.30 · 103 mm2/s) than in the
598 F.Z. Moukhtar, A.A. Abu El Maatimalignant group (1.02 ± 0.29 · 103 mm2/s, p< 0.01). In the NMLE type, the mean ADC is also
higher in the benign group (1.54 ± 0.45 · 103 mm2/s) than in the malignant group
(1.11 ± 0.32 · 103 mm2/s, p< 0.01). Therefore, benign lesions have higher ADC values than
malignant lesions, regardless of the lesion morphology.
Conclusion: Diffusion-weighted MRI shows adequate help in differentiation of benign and malig-
nant masses and lesions with non-mass like enhancement found at breast MRI.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Magnetic resonance (MR) imaging has been increasingly used
for accurate diagnosis of both primary and recurrent breast
cancers, particularly in cases in which mammography and
breast sonography are inconclusive or yield discrepancies. In
addition, MR imaging may improve the analysis of the local
extent of breast cancer by revealing multifocal and multicenter
tumor growth in patients scheduled for conservative breast
surgery (1). Classic breast magnetic resonance imaging
(MRI) is based on the enhancement pattern of lesions in
DCE-MRI, and morphologic changes (2). With these two cri-
teria breast MRI has a sensitivity of about 85–99% in detect-
ing malignant breast lesions (3). MRI has high sensitivity
(89–100%) but lacks speciﬁcity for characterizing breast
tumors (4). The American College of Radiology (ACR)
BI-RADS MRI lexicon is used worldwide for describing the
morphologic and kinetic features of breast lesions. It allows
standardization of the terminology used for description of
the ﬁndings and categorization of the study. According to
BI-RADS, morphologic analysis is done by evaluating the
shape, margin, and enhancement characteristics of the masses
and distribution and internal enhancement pattern of the non
mass lesions. Kinetic analysis is done by evaluating the initial
enhancement rate and post initial enhancement of the lesions
(5). Although certain lesion characteristics, such as irregular
or spiculated margin, rim enhancement, ductal or segmental
enhancement, and rapid initial enhancement with a wash-out
course are highly suggestive of malignancy, certain lesion char-
acteristics, such as smooth margin, enhancement less than the
surrounding breast parenchyma, and non enhancing internal
septations are highly suggestive of benign disease (6). Finally,
MRI studies are inserted into one of the six BI-RADS catego-
ries and appropriate recommendation is made (5). In spite of
all these efforts, an overlap between the MRI ﬁndings of be-
nign and malignant lesions still exists, resulting in variable
speciﬁcity (50–90%) (7). Because of this confounding overlap,
in some cases it is not possible to make the differential diagno-
sis between benign and malignant lesions on the basis of con-
ventional MRI features (8).
To further increase the speciﬁcity of DCE-MRI, research
on new MRI techniques is being conducted. Diffusion-
weighted imaging (DWI) was recently integrated into the
standard breast MRI examination for this purpose. Diffu-
sion-weighted imaging (DWI) is an unenhanced MRI sequence
that measures the mobility of water molecules in vivo and pro-
vides different and potentially complementary information to
DCE-MRI (9). It is a noninvasive technique that characterizes
the tissues with a mechanism that is different from T1 and T2
relaxation. The motion of water protons in the tissue isaffected by ﬂuid viscosity, membrane permeability, blood ﬂow,
and cellularity of the tissue. For the quantiﬁcation of this mo-
tion, apparent diffusion characteristic (ADC) values are used
(10).
By using the DWI sequence, one can calculate the appar-
ent diffusion coefﬁcient (ADC), a quantitative measure that is
directly proportional to the water diffusion (11). High cell
proliferation in malignant tumors increases cellular density,
creating more barriers to the extracellular water diffusion,
reducing the ADC, and resulting in signal loss. This sequence
appears to be a useful tool for tumor detection and character-
ization (12), as well as for monitoring and predicting treat-
ment response (13).
Recent studies have proven the potential of ADC to differ-
entiate breast tumors (7,12,14). These studies used different b
values, varying from 0 to 1000 s/mm2, and found a signiﬁcant
difference in the ADC value between malignant and benign
lesions, with a sensitivity ranging from 81% to 93% and
speciﬁcity from 80% to 88%, for an ADC cutoff of
1.1–1.3 · 103 mm2/s (14).
In addition to differences between different histological
types, differences in ADC values between different morpholog-
ical types, such as mass and non-mass-like enhancement
(NMLE), have also been shown (15–17). According to the
BI-RADS (Breast Imaging Reporting and Data System) lexi-
con, a mass is a three-dimensional lesion with clear boundaries
that occupies a space within the breast.
Non-mass-like enhancement (NMLE) refers to lesions with
abnormal enhancement larger than focus but without
space-occupying effect. Notably, it is often mentioned as
‘‘non-mass-like enhancement’’ rather than ‘‘non-mass lesion’’.
Different from mass, NMLE can have stippled or patchy nor-
mal gland tissues or fat inside it. NMLE should be described
from its morphology and internal enhancement pattern (18).
The aim of the study is to investigate the diagnostic value of
the ADC, measured by diffusion-weighted MRI, as an adjunct
to DCE-MRI for the diagnosis of breast lesions presenting as
mass and NMLE.
2. 2.Patients and methods
2.1. Patients
A total of 80 patients with 110 breast lesions identiﬁed at
DCE-MRI between July 2012 and May 2013 were reviewed.
The inclusion criteria used for diagnostic purposes included
the following: pathology conﬁrmation; no intervention within
3 months (no biopsy or surgery); lesions <5 mm were ex-
cluded from this study (too small for ADC measurements).
Using these inclusion and exclusion criteria, a total of 80
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identiﬁed. Of these, the histological types in 50 patients were
conﬁrmed through surgical specimens, and the other 30
patients underwent ultrasound- or mammography-guided
biopsy. MRI was used for diagnostic purposes, and all exam-
inations were completed before the performance of needle
biopsy or surgical excision. The age of the patients ranged
from 25 to 75 years (mean ± SD, 46.3 ± 10.4), and lesion
sizes ranged from 0.7 to 8.2 cm.
2.2. MR imaging protocol
MRI was performed using a dedicated four-channel phased
array breast coil on a 1.5 T MRI scanner (Signa Excite HD
Twin, General Electric Healthcare, Milwaukee, USA). Patients
were scanned in the prone position. The imaging protocol in-
cluded four pulse sequences, with a total scan time of approx-
imately 20 min. DWI was performed with the following
parameters: spin-echo echo-planar-imaging sequence (SE-
EPI), TR 8400 ms, TE 93.8 ms, ASSET factor 2, b value 0,
and 750/mm2, 2NEX (Number of Excitation), matrix
128 · 128, FOV (ﬁeld of view) 340 · 340 mm, 4 mm thickness,
and 1 mm gap. T2-weighted imaging (T2WI) was performed
with the following parameters: fast spin echo sequence, chem-
ical shift selective fat saturation, TR 4660 ms, TE 89.2 ms,
echo trained length 12, 2NEX, matrix 320 · 256, FOV
340 · 340 mm, 4 mm thickness, and 1 mm gap. T1-weighted
imaging (T1WI) was performed with the following parameters:
spin echo sequence (SE), TR 500 ms, TE 8.3 ms, 2NEX, matrix
320 · 224, FOV 340 · 340 mm, 4 mm thickness, and 1 mm
gap. DWI, T2WI, and T1WI were spatially matched on the ax-
ial plane, with 32 slices (4 mm thickness and 1 mm gap) cover-
ing the whole breast and the axillary fossa. The fourth
sequence used was DCE imaging and was also performed on
the axial plane. The VIBRANT (Volume Imaging for Breast
Assessment) sequence is a spectrally selective inversion recov-
ery three-dimensional spoiled gradient recalled sequence. The
imaging parameters as follows: TR 4.7 ms, TE 2.2 ms, ﬁeld
of view 320 · 320 mm, matrix 384 · 320, and 1.2 mm slice
thickness, yield a near isotropic resolution of
0.83 · 0.9 · 1.2 mm. The temporal resolution was 120 s, and
six phases were acquired. The contrast agent, Gd-BOPTA
(0.1 mmol/kg body weight), was injected at a rate of 2 ml/s,Table 1 The MRI morphological types, the histological diagnosis,
MRI type Diagnosis Histolo




Malignant (N= 48) DCIS
IDC
Lobula




Malignant (N= 27) DCIS
IDCfollowed by 20 ml saline ﬂushing immediately after the acqui-
sition of the ﬁrst pre-contrast phase was completed.
2.3. MRI interpretation
An experienced radiologist (with 10 years of experience in
breast MRI) reviewed the images and performed the ADC
measurements. The lesions were classiﬁed into the following
three MRI morphological types, with strict adherence to the
American College of Radiology BI-RADS MRI lexicon: fo-
cus/foci, mass, and NMLE. The focus/foci lesions (smaller
than 5 mm) were too small for ADC measurements, and they
were excluded in this study. The morphological types were
mainly deﬁned on the enhanced DCE images (mass and
NMLE lesions).
2.4. Image analysis
The ROI was drawn freehand on the DWI images to include
the most hyperintense portion of the lesion shown on DWI
or to include the area showing the highest contrast enhance-
ment by using the contrast-enhanced images as references.
For each case, up to six ROIs were placed within the lesion,
but only the lowest ADC value was used in the statistical anal-
ysis. Care was taken to avoid areas of T2 shine-through, such
as cyst and necrosis; by comparing the diffusion weighted
images with T2 weighted images and ADC maps.
2.5. Statistical analysis
SPSS statistical software package (Version 17) was used for
data analysis. Data were expressed as mean ± SD for quanti-
tative measures. Using Student’s t test P> 0.05 was consid-
ered statistically non signiﬁcant, P< 0.05 was considered
statistically signiﬁcant and P< 0.01 was considered statisti-
cally highly signiﬁcant.
3. Results
Of the 110 lesions, 71(64%) were classiﬁed as mass and 39
(35%) were classiﬁed as NMLE. The MASS group consisted
of 48 (68%) malignant lesions and 23 (32%) benign lesions.and the ADC values.
gical type N ADC value (mean ± SD)
denosis 5 1.40 ± 0.31
enoma 13 1.41 ± 0.29
hyperplasia 4 1.20 ± 0.14
ing adenosis 1 1.26 ± 0.26
10 1.30
20 0.97 ± 0.18
r carcinoma 12 1.2
denosis 10 1.71 ± 0.35
enoma 2 1.15 ± 0.49
hyperplasia 2 1.60
ing adenosis 3 1.70
21 1.22 ± 0.36
10 1.05 ± 0.29
Table 2 The mean ADC values (·103 mm2/s) of benign and
malignant lesions in mass and NMLE types.
MRI morphological types Benign Malignant
Mass 1.34 ± 0.30 1.02 ± 0.29
NMLE 1.54 ± 0.45 1.11 ± 0.32
Mass + NMLE 1.41 ± 0.36 1.05 ± 0.30
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12 (31%) benign lesions.
75 lesions (68%) were neoplastic: DCICS (n= 33), IDC
(invasive duct carcinoma) (n= 30), lobular carcinoma
(n= 12) and 35 lesions (32%) were benign: focal adenosis
(n= 15), ﬁbroadenoma (n= 10), ductal hyperplasia (n= 6),
and sclerosing adenosis (n= 4). The MRI morphological
types of different lesions included in the study, their histolog-
ical diagnosis, and their mean ADC values are summarized on
Table 1.
The mean ADC value of all benign lesions is
1.41 ± 0.36 · 103 mm2/s, which is higher than the mean
ADC of all malignant lesions (1.05 ± 0.30 · 103 mm2/s,
p< 0.05). In the MASS type, the mean ADC is higher in
the benign group (1.34 ± 0.30 · 103 mm2/s) than in the(a)
(c)   
Fig. 1 A 43-year old female patient presented with right breast m
weighted sequence with fat-suppression, (b) axial diffusion weighted se
lesion with benign morphology and contrast enhancement pattern. Th
value of 1.4 · 103. It was pathologically proven to be a ﬁbroadenommalignant group (1.02 ± 0.29 · 103 mm2/s, p< 0.01). In
the NMLE type, the mean ADC is also higher in the benign
group (1.54 ± 0.45 · 103 mm2/s) than in the malignant group
(1.11 ± 0.32 · 103 mm2/s, p< 0.01), (Table 2). Therefore,
benign lesions have higher ADC values than malignant lesions,
regardless of the lesion morphology.
Regarding the ADC values in different histological sub-
types, the DCIS, IDC and benign localized adenosis were the
most commonly encountered lesions. The mean ADC of the
malignant IDC group was 0.99 ± 0.22 · 103 mm2/s, which
was signiﬁcantly lower than that of the DCIS group
(1.23 ± 0.33 · 103 mm2/s, p< 0.01) and the benign adenosis
group (1.52 ± 0.35 · 103 mm2/s, p< 0.01). The ADC of the
DCIS group was also signiﬁcantly lower than the ADC of the
adenosis group (p< 0.01). The rest of the histological sub-
types included in the study was few in number so no statisti-
cally signiﬁcant comparison could be done.
In the study group as a whole, the optimal cutoff value
found to differentiate benign from malignant lesions was
1.25 · 103 mm2/s, with a sensitivity of 82%, a speciﬁcity of
68%, and an overall accuracy of 78%. When taking MRI mor-
phological types into consideration, the optimal cutoff ADC
value for MASS type lesions was 1.05 · 103 mm2/s, which re-
sulted in a sensitivity of 70%, a speciﬁcity of 85%, and an
accuracy of 81%. In the NMLE type lesions, the cutoff                       (b)
                      (d) 
ass. (a) Delayed phase contrast-enhanced 3D gradient axial T1
quence (b 750 s/mm2), (c and d) axial ADC map showed one mass
e mass shows bright signal on DWI with the corresponding ADC
a.
(a)                               (b)                                      (c)
(d)                                (e)                                    (f)
Fig. 2 36-Year old female patient presented with left sided breast pain and heaviness. (a–c) Axial 3D gradient T1 weighted sequence with
fat suppression at early post contrast phase, (d–f) axial diffusion weighted sequence and the corresponding ADC map revealed multiple
lobulated nodules at different quadrants with suspicious contrast enhancement. Note that nodules show high signal intensity on the
diffusion (arrow) and signal loss on the ADC map with a mean ADC value of 0.9 · 103. It was pathologically proven to be multicenteric
invasive ductal carcinoma.
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83%, a speciﬁcity of 74%, and an accuracy of 77%.
Five case examples are presented. Fig. 1 shows a mass ﬁbro-
adenoma lesion with bright signal on diffusion and no signal
loss on ADC map. Fig. 2 shows multiple mass lesions, diag-
nosed as multicentric IDC. Fig. 3 shows a pure DCIS NMLE
lesion. Fig. 4 shows a relatively large mass lesion with bright
signal on diffusion and signiﬁcant signal drop on ADC map
and with signiﬁcantly lower ADC value compared to lesions
on cases 1 and 5 Lastly, Fig. 5 illustrates a benign NMLE ade-
nosis lesion.4. Discussion
The present study evaluated the role played by the diffusion-
weighted sequence in the differentiation between benign and
malignant lesions.
We found that malignant tumors had signiﬁcantly lower
ADCs than benign lesions for both masses and lesions with
non-mass like enhancement and that the diagnostic perfor-
mance of DWI based on ADC thresholds was comparable
for both lesion types. We observed that the difference in mean
ADC of benign and malignant lesions was smaller for lesions
with non-mass like enhancement than for masses. The meanADC for malignant lesions with non-mass like enhancement
was higher than that of malignant masses. Lesions with non-
mass like enhancement are commonly characterized as having
a diffuse distribution, clumped or stippled enhancement (5)
and tend to replace rather than displace the normal breast
parenchyma. Therefore, ADC measurement of lesions with
non-mass like enhancement may involve more partial volume
averaging with normal tissue than would ADC measurement
of more focal mass-type lesions. In addition, the results may
explain why the differences in ADC between benign and malig-
nant lesions were smaller for lesions with non-mass like
enhancement than for masses. This observation may have par-
ticular implications for discriminating ductal carcinoma
in situ, which usually has non-mass like enhancement (19).
Partridge et al. compared the use of ADC in discriminating
benign from malignant lesions that were presented as mass
type and NMLE type and found that the diagnostic accuracy
is higher for mass than for NMLE lesions; however, the differ-
ence was not signiﬁcant (15). Imamura et al. compared the
ADC of malignant and benign NMLE lesions and found a
slightly higher mean ADC in the benign compared with the
malignant groups; the difference was not signiﬁcant (20). The
number of NMLE cases analyzed in these two studies was rel-
atively small, which may have limited the power to yield signif-
icant results.
(a)                                             (b)
(c)                                                     (d)
Fig. 3 30-Year old patient came for check up. (a) Axial 3D gradient T1 weighted sequence with fat suppression at early post contrast
phase, (b) axial diffusion weighted sequence and the corresponding ADC map (c and d) revealed bilateral linear branching ductal
enhancement, which showed high signal intensity on DWI with signal drop on ADC map, with ADC value of 0.9 · 103 on the right side
and 0.3 · 103 on the left side. It was pathologically proven to be DCIS with minimal invasion.
(a)                                            (b)                                 
(c)                                                 (d)                                      
Fig. 4 43-Year old patient presented with left sided breast mass. (a) Axial 3D gradient T1 weighted sequence with fat suppression at
early post contrast phase, (b) axial diffusion weighted sequence and the corresponding ADC map (c and d) revealed a large lobulated
inﬁltrative mass lesion with suspicious contrast enhancement. Note that the nodule shows high signal intensity on the diffusion (arrow)
and signal loss on the ADC map with an ADC value of 0.5 · 103. It was pathologically proven to be inﬁltrating lobular carcinoma.
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mobility caused by tissue alterations associated with patholog-
ical processes. Thus, the measurement of the water molecule’s
motion provides additional information that may determine an
increase in the MRI speciﬁcity in the classiﬁcation of breast
lesions. Previous studies with diffusion-weighted MRI have
shown promising results in the differentiation between benignand malignant lesions with sensitivity ranging from 81% to
93% and speciﬁcity ranging from 80% to 88.5%
(7,12,16,21,22). But there are only a few studies comparing
its respective diagnostic value in mass and NMLE lesions
(15–17). The results of the present study are in agreement with
these previous studies, demonstrating statistical differences be-
tween benign and malignant lesions.
(a)                                                             (b)
(c) (d)
Fig. 5 A 35 year old female patient on regular check up where an ill deﬁned speculated lesion was found on mammography with
associated tiny focus of micro calciﬁcation. (a) Axial 3D gradient T1 weighted sequence with fat suppression at early post contrast phase,
(b) axial diffusion weighted sequence and the corresponding ADC map (c and d) revealed one mass lesion in the right upper outer region
of the breast.
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lesions vary between studies, making it difﬁcult to set an opti-
mal value for differential diagnosis. Many biological and
technical factors may contribute to the different reported
ADC values. It has been consistently shown that invasive can-
cers have lower ADC values than non-invasive cancers (mainly
ductal carcinoma in situ) (18,21,23,24). Therefore, the reported
mean ADC of malignant lesions in different studies would
vary depending on the number of respective invasive ductal
carcinoma (IDC) and ductal carcinoma in situ (DCIS) cases
that were included in the analysis. Similarly, there are many
histological types of benign tumors, and their different cellular
structures will result in different ADC values. Therefore, the
reported mean ADC of benign lesions would also depend on
the different histological types included in the analysis.
In our study, we found that the mean ADC was signiﬁcantly
lower for the entire IDC group (0.99 ± 0.22 · 103 mm2/s)
than the DCIS group (1.23 ± 0.33 · 103 mm2/s), which was
lower than the benign adenosis group (1.52 ± 0.35 ·
103 mm2/s. This was attributed to the fact that the decrease
in cell density is related to the aggressiveness of the lesion.
IDC lesions are commonly characterized as densely packed
tumor cells, lacking ﬁbrous stroma, whereas DCIS has a lower
density of tumor cells with abundant ﬁbrous stroma (26).
However, the relationship between ADC and cellularity re-
mains controversial. Our results agreed with some studies that
demonstrated an inverse relationship between ADC and cell
density (25,26), whereas others suggested no signiﬁcant corre-
lation (24). Breast lesions are highly heterogonous; therefore,this discrepancy may be due to different histological types in-
cluded in the studies or analysis methods that were used to
measure ADC. In our study, the lowest ADC value from all
examined ROIs within a lesion was used in the analysis. The
advantage of this method compared with the averaging ADC
values from the entire lesion is that the ADC from the most
aggressive tissue component within the lesion was used to rep-
resent the lesion.
5. Conclusion
By combining ADC measurements and dynamic studies with
interpretation of enhancement patterns, the latter known to
have good sensitivity but variable speciﬁcity for characterizing
lesions, the overall accuracy of MRI can be increased, reducing
unnecessary invasive procedures.
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